RxDoctor Payments Data

Shelly Clary

Family · Statesboro, GANPI 1437557287

Payments from drug & device makers

$7,751in general payments, 2019–2025

Across 391 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$834
  • Lilly USA, LLC$507
  • GSK$492
  • AstraZeneca$487
  • Amgen$457
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$7,751100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,751 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$37,847
Medicare patients
222
Services billed
605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$33,538
MounjaroTirzepatide27$29,032
JanuviaSitagliptin Phosphate27$26,347
OzempicSemaglutide20$24,154
Tresiba Flextouch U-200Insulin Degludec11$15,852
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$15,257
Janumet XrSitagliptin Phos/Metformin Hcl15$14,108
FarxigaDapagliflozin Propanediol22$13,664
JardianceEmpagliflozin13$12,303
Tresiba Flextouch U-100Insulin Degludec11$8,815
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$7,562
SymbicortBudesonide/Formoterol Fumarate15$5,402
SynthroidLevothyroxine Sodium40$3,933
Novolog FlexpenInsulin Aspart14$2,681
Gabapentin102$1,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$492$41,10051 claims
MerckJanuvia, Janumet Xr$135$40,45442 claims
Lilly USA, LLCMounjaro$507$29,03227 claims
Novo NordiskOzempic$834$24,15420 claims
AstraZenecaFarxiga, Symbicort$487$19,06737 claims
Boehringer IngelheimJardiance$324$12,30313 claims
AbbVieSynthroid$1,139$3,93340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →